THC Global Group Ltd (ASX:THC) non-executive director Gary Radcliff has demonstrated his confidence in the company's medicinal cannabis strategy with the purchase of shares in an on-market transaction.
On September 7 Radcliff purchased 44,900 shares in an indirect interest, increasing the total number of securities held to 207,516 shares.
Strategic review
The company is undergoing an executive restructure in parallel with a strategic and operational review.
Corporate growth initiatives and taking advantage of THC’s existing ‘significant’ investment in pharmaceutical medicinal cannabis manufacturing assets is set to be the focus of the review
The restructure involves Ken Charteris standing down as the group's chief effective officer immediately and being replaced by Jarrod White as interim chief executive officer.
THC will undertake a global executive search for a new fulltime CEO with appropriate experience and expertise in medicinal cannabis and pharmaceutical manufacturing.
